DAVID ALLISON to Double-Blind Method
This is a "connection" page, showing publications DAVID ALLISON has written about Double-Blind Method.
Connection Strength
0.300
-
Randomized controlled trial examining expectancy effects on the accuracy of weight measurement. Clin Obes. 2015 Feb; 5(1):38-41.
Score: 0.088
-
Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res. 2009 Dec 30; 170(2-3):172-6.
Score: 0.062
-
No evidence for a major role of polymorphisms during bupropion treatment. Obesity (Silver Spring). 2006 Nov; 14(11):1863-7.
Score: 0.050
-
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord. 2004 Nov; 28(11):1411-9.
Score: 0.044
-
A randomized cross-over trial to determine the effect of a protein vs. carbohydrate preload on energy balance in ad libitum settings. Nutr J. 2019 11 09; 18(1):69.
Score: 0.031
-
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
Score: 0.018
-
Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998 Nov 11; 280(18):1596-600.
Score: 0.007